Wen Hsieh is a general partner at Kleiner Perkins Caufield & Byers U.S. He is also a managing partner of KPCB China and leads the Greentech practice there. Since joining the firm in 2006, he has focused on early-stage investments and incubations in green technologies, such as energy storage, fuel cells, renewable fuels and chemicals, and solar PV, as well as disruptive semiconductor and hardware innovations. Wen works closely with the teams at Alta Devices, Amprius, Bloom Energy, Crossbar, LuxVue, mCube, PVNext, Solexel, Spatial Photonics and SuVolta as a board director or observer. He also advocated KPCB’s early investment in Amyris Biotechnologies (Nasdaq: AMRS), and as a board observer, he supported Amyris from Series A through IPO.
Before joining KPCB, Wen was an Associate Principal at McKinsey & Co. San Francisco and a leader of McKinsey’s Asia semiconductor practice. During his five years at McKinsey, Wen focused primarily on serving leading companies across the global semiconductor value chain. His clients included EDA companies, IC design houses, wafer fab equipment vendors, automated test equipment suppliers, test solution providers, wafer foundries, logic and memory IDMs, PC and server OEMs and electronic component distributors. His secondary focus at McKinsey was on the North America biopharma sector, where his clients were small companies in the anti-viral, generics and specialty pharma segments. Earlier in his career, Wen founded OnChip Technologies, a startup developing MEMS microfluidic biochips. The company’s target market was high-sensitivity and high-throughput peptide separation and identification applications.
Wen earned a Ph.D. in electrical engineering and a Ph.D. minor in biology from the California Institute of Technology. He also received a B.S. degree with honors and an M.S. degree in electrical engineering from the same institution.